We’re Collecting Info on Adbry™ When Taken in Pregnancy
MotherToBaby is currently enrolling participants into an observational study examining the use of Adbry™ (tralokinumab-ldrm) when taken during pregnancy. Our research is by observation only—we will not ask you to take or change any medications. If you join our Adbry™ (tralokinumab-ldrm) study, our team will simply collect some information about your pregnancy and your baby’s development for a period of time after birth.
“Help us improve the ability for pregnant people and their healthcare providers to make more informed treatment decisions by joining our Adbry™ (tralokinumab-ldrm) & pregnancy study.”— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies
Our Adbry™ (tralokinumab-ldrm) study includes:
Our study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your and your baby’s medical records from your healthcare providers.
• An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor
• A neurodevelopmental assessments that can also provide insight into the child’s development at approximately 4 months and 12 months of age
If you have moderate-to-severe eczema (atopic dermatitis) and have taken Adbry™ (tralokinumab-ldrm) at any point in your current pregnancy or 3 months prior to pregnancy, you may qualify for this important study.
Will you take the next step and help us learn more about the use of Adbry™ (tralokinumab-ldrm) during pregnancy?